The plaintiffs in the Effexor XR
case have challenged a patent settlement agreement between drug manufacturers Wyeth and Teva Pharmaceuticals, alleging that Teva agreed to delay introduction of its generic version of Wyeth's blockbuster antidepressant drug Effexor XR
until July 1, 2010, and that Wyeth agreed not to market an authorized generic version of Effexor XR
for a period of time.
5 mg (base), 75 mg (base) and 150 mg (base), the generic version of Wyeth's Effexor XR
Wyeth-Ayerst Antidepressant (serotonin/ norepinephrine reuptake inhibitor) 14.
In other countries (eg, South Africa), the generic Effexor XR
came out even earlier and one generic company, Ciplo Medpro  , are already legally manufacturing and selling extended release venlafaxine capsules under the brand name Venlor XR in that country.
The site also provides information on Connexions, a patient and caregiver support program; hyperlinks to other important mental health resource sites; a glossary of mental health terms; quick facts; and clinical information about EFFEXOR XR
(venlafaxine HCl) Extended-Release Capsules, the first and only antidepressant indicated to treat both depression and GAD.
In the study, 69 percent or more of patients treated with Effexor XR
showed significant improvements in symptoms of GAD for up to six months, compared with 42 to 46 percent given a placebo.
According to CVS and Rite Aid's suit, Pfizer's Wyeth unit schemed with Teva, a generic manufacturer, to prevent other generic versions of Effexor XR
from reaching store shelves for at least two years after its exclusive marketing rights to the drug expired in June 2008.
This product is the Israeli company's generic version of Wyeth's antidepressant Effexor XR
Wyeth's new version of the drug, Effexor XR
, doesn't lose patent protection until 2010.
The choice of Seroquel vs Geodon or Lexapro vs Effexor XR
increasingly becomes our only choice in a society of ever-deepening disintegration and desperation, in which the easy and quick becomes the unquestioned norm and psychiatrist-diagnosed mental illness is more common.
In both studies, patients given Effexor XR
showed significant improvements in symptoms of GAD for up to six months, compared with those given a placebo.
The depression therapeutics market will witness the patent expiry of Lexapro in 2012, Cymbalta in 2013 and Effexor XR